ANTI-CANCER PHARMACEUTICAL COMPOSITION

[Object] An object is to provide an anti-cancer pharmaceutical composition for prophylaxis or treatment of carcinoma, sarcoma or hematopoietic cancer. [Means to Solve the Problem] An anti-cancer pharmaceutical composition comprising a compound represented by the following general formula (I): (see formula I) [wherein, R represents a phenyl group substituted with 1 to 5 substituents selected from a halogen atom; a hydroxy group; a C1-C6 alkyl group; a halogeno C1-C6 alkyl group; a C1-C6 alkoxy group; a C1-C6 alkylthio group; an amino group which may be substituted with a substituent; a C3-C10 cycloalkyl, C6-C10 aryl, C7-C16 aralkyl, C6-C10 aryloxy, C7-C16 aralkyloxy and C6-C10 arylthio group which may be substituted with a substituent; a C1-C7 aliphatic acyloxy group; a 4- to 7-membered saturated heterocyclic group containing nitrogen atom(s); a 5- or 6-membered aromatic heterocyclic group containing nitrogen atom(s); a nitro group; and a cyano group; and X represents an oxygen atom or a sulfur atom] or a pharmacologically acceptable salt thereof, as an active ingredient, and an anti-cancer pharmaceutical composition for prophylaxis or treatment of carcinoma, sarcoma or hematopoietic cancer which is for administering simultaneously or separately at different times, containing an epidermal growth factor receptor (EGFR) inhibitor, a vascular endothelial growth factor receptor (VEGFR) inhibitor or a Raf kinase inhibitor; and a compound represented by the aforementioned general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient.